Temporal changes in concentrations of lipids and apolipoprotein B among adults with diagnosed and undiagnosed diabetes, prediabetes, and normoglycemia: Findings from the National Health and Nutrition Examination Survey 1988-1991 to 2005-2008

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Ford, Earl S ^a   Li, Chaoyang ^b   Sniderman, Allan ^c  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Apolipoprotein B; Cholesterol; Diabetes; Fenofibrate; Gemfibrozil; High density lipoprotein cholesterol; Lipids; Niacin; Prediabetes; Triglycerides

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; FENOFIBRATE; GEMFIBROZIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; TRIACYLGLYCEROL;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG USE; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH SURVEY; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL ASSESSMENT;

ADULT; APOLIPOPROTEINS B; BLOOD GLUCOSE; DIABETES MELLITUS; FEMALE; GLYCEMIC INDEX; HUMANS; LIPIDS; MALE; MIDDLE AGED; NUTRITION SURVEYS; PREDIABETIC STATE; TIME FACTORS; UNITED STATES;

EID: 84873031959     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-26     Document Type: Article

References (41)

1. Fox CS, Pencina MJ, Meigs JB, Vasan RS, Levitzky YS, D'Agostino RB. Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: the Framingham Heart Study. Circulation 2006, 113:2914-2918. 10.1161/CIRCULATIONAHA.106.613828, 16785337.
2. Cowie CC, Rust KF, Ford ES, Eberhardt MS, Byrd-Holt DD, Li C, Williams DE, Gregg EW, Bainbridge KE, Saydah SH, et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care 2009, 32:287-294. 2628695, 19017771.
3. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA 2003, 290:1884-1890. 10.1001/jama.290.14.1884, 14532317.
4. Centers for Disease Control and Prevention National Diabetes Fact Sheet 2011, http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf, Centers for Disease Control and Prevention.
5. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di AE, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010, 375:2215-2222. 10.1016/S0140-6736(10)60484-9, 2904878, 20609967.
6. National Diabetes Education Program The Link Between Diabetes and Cardiovascular Disease http://www.ndep.nih.gov/media/CVD_FactSheet.pdf, National Diabetes Education Program.
7. Brunzell JD, Ayyobi AF. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med 2003, 115(Suppl 8A):24S-28S.
8. Preis SR, Pencina MJ, Hwang SJ, D'Agostino RB, Savage PJ, Levy D, Fox CS. Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study. Circulation 2009, 120:212-220. 10.1161/CIRCULATIONAHA.108.846519, 2789428, 19581493.
9. Hoerger TJ, Zhang P, Segel JE, Gregg EW, Narayan KM, Hicks KA. Improvements in risk factor control among persons with diabetes in the United States: evidence and implications for remaining life expectancy. Diabetes Res Clin Pract 2009, 86:225-232. 10.1016/j.diabres.2009.09.017, 19833403.
10. Ford ES. Trends in the control of risk factors for cardiovascular disease among adults with diagnosed diabetes: findings from the National Health and Nutrition Examination Survey 1999-2008. J Diabetes 2011, 3:337-347. 10.1111/j.1753-0407.2011.00148.x, 21767347.
11. Sniderman AD, Williams K, McQueen MJ, Furberg CD. When is equal not equal?. J Clin Lipidol 2010, 4:83-88. 10.1016/j.jacl.2010.01.005, 21122634.
12. Centers for Disease Control and Prevention Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94 1994, 1-407. Vital Health Stat Series 1 no 32) (DHHS publication no (PHS) 94-1308, Centers for Disease Control and Prevention.
13. Centers for Disease Control and Prevention About the National Health and Nutrition Examination Survey http://www.cdc.gov/nchs/nhanes/about_nhanes.htm, Centers for Disease Control and Prevention.
14. Stevens RJ, Kothari V, Adler AI, Stratton IM. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 2001, 101:671-679.
15. Sniderman AD. How, when, and why to use apolipoprotein B in clinical practice. Am J Cardiol 2002, 90:48i-54i.
16. Di AE, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302:1993-2000. 3284229, 19903920.
17. Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, De GJ, Furberg CD. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011, 4:337-345. 10.1161/CIRCOUTCOMES.110.959247, 21487090.
18. Harper CR, Jacobson TA. Using apolipoprotein B to manage dyslipidemic patients: time for a change?. Mayo Clin Proc 2010, 85:440-445. 10.4065/mcp.2009.0517, 2861973, 20435837.
19. Ramjee V, Sperling LS, Jacobson TA. Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math. J Am Coll Cardiol 2011, 58:457-463. 10.1016/j.jacc.2011.05.009, 21777740.
20. Preis SR, Hwang SJ, Coady S, Pencina MJ, D'Agostino RB, Savage PJ, Levy D, Fox CS. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 2009, 119:1728-1735. 10.1161/CIRCULATIONAHA.108.829176, 2789419, 19307472.
21. Gregg EW, Cheng YJ, Saydah S, Cowie C, Garfield S, Geiss L, Barker L. Trends in death rates among u.s. Adults with and without diabetes between 1997 and 2006: findings from the national health interview survey. Diabetes Care 2012, 35:1252-1257. 10.2337/dc11-1162, 22619288.
22. Wright JD, Wang CY. Trends in intake of energy and macronutrients in adults from 1999-2000 through 2007-2008. NCHS Data Brief 2010, 1:8.
23. National Center for Health Statistics Health, United States, 2011: With Special Feature on Socioeconomic Status and Health 2012, Hyattsville, MD, National Center for Health Statistics.
24. Church TS, Thomas DM, Tudor-Locke C, Katzmarzyk PT, Earnest CP, Rodarte RQ, Martin CK, Blair SN, Bouchard C. Trends over 5 decades in U.S. occupation-related physical activity and their associations with obesity. PLoS One 2011, 6:e19657. 10.1371/journal.pone.0019657, 3102055, 21647427.
25. LaVallee RA, Yi H-Y. Apparent per capita alcohol consumption: national, state, and regional trends, 1977-2009 2011, Bethesda, MD.
26. Wagner AM, Ordonez-Llanos J, Caixas A, Bonet R, De LA, Perez A. Quantitative effect of glycaemic improvement on the components of diabetic dyslipidaemia: a longitudinal study. Diabetes Res Clin Pract 2005, 68:81-83. 10.1016/j.diabres.2004.07.018, 15811569.
27. Blumenthal KJ, Larkin ME, Winning G, Nathan DM, Grant RW. Changes in glycemic control from 1996 to 2006 among adults with type 2 diabetes: a longitudinal cohort study. BMC Health Serv Res 2010, 10:158. 10.1186/1472-6963-10-158, 2889946, 20534158.
28. Cho DS, Woo S, Kim S, Byrne CD, Kong JH, Sung KC. Estimation of plasma apolipoprotein B concentration using routinely measured lipid biochemical tests in apparently healthy Asian adults. Cardiovasc Diabetol 2012, 11:55. 10.1186/1475-2840-11-55, 3458889, 22607125.
29. Jiang R, Schulze MB, Li T, Rifai N, Stampfer MJ, Rimm EB, Hu FB. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care 2004, 27:1991-1997. 10.2337/diacare.27.8.1991, 15277429.
30. Bruno G, Merletti F, Biggeri A, Bargero G, Prina-Cerai S, Pagano G, Cavallo-Perin P. Effect of age on the association of non-high-density-lipoprotein cholesterol and apolipoprotein B with cardiovascular mortality in a Mediterranean population with type 2 diabetes: the Casale Monferrato study. Diabetologia 2006, 49:937-944. 10.1007/s00125-006-0195-6, 16525840.
31. Stettler C, Suter Y, Allemann S, Zwahlen M, Christ ER, Diem P. Apolipoprotein B as a long-term predictor of mortality in type 1 diabetes mellitus: a 15-year follow up. J Intern Med 2006, 260:272-280. 10.1111/j.1365-2796.2006.01690.x, 16918825.
32. Taskinen MR, Barter PJ, Ehnholm C, Sullivan DR, Mann K, Simes J, Best JD, Hamwood S, Keech AC. Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes. Diabetologia 2010, 53:1846-1855. 10.1007/s00125-010-1806-9, 20526762.
33. Sasongko MB, Wong TY, Nguyen TT, Kawasaki R, Jenkins A, Shaw J, Wang JJ. Serum apolipoprotein AI and B are stronger biomarkers of diabetic retinopathy than traditional lipids. Diabetes Care 2011, 34:474-479. 10.2337/dc10-0793, 3024371, 21270203.
34. Hegele RA, Harris SB, Zinman B, Hanley AJ, Connelly PW. Increased plasma apolipoprotein B-containing lipoproteins associated with increased urinary albumin within the microalbuminuria range in type 2 diabetes. Clin Biochem 1999, 32:143-148. 10.1016/S0009-9120(98)00101-5, 10211632.
35. Tseng CH. Apolipoprotein B is an independent risk factor for microalbuminuria in Taiwanese patients with type 2 diabetes. Diabetes Care 2003, 26:2965-2966. 10.2337/diacare.26.10.2965, 14514620.
36. Matsumoto K, Fujita N, Nakamura K, Senoo T, Tominaga T, Ueki Y. Apolipoprotein B and insulin resistance are good markers of carotid atherosclerosis in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2008, 82:93-97. 10.1016/j.diabres.2008.06.018, 18684539.
37. Dahlen EM, Lanne T, Engvall J, Lindstrom T, Grodzinsky E, Nystrom FH, Ostgren CJ. Carotid intima-media thickness and apolipoprotein B/apolipoprotein A-I ratio in middle-aged patients with Type 2 diabetes. Diabet Med 2009, 26:384-390. 10.1111/j.1464-5491.2009.02693.x, 19388968.
38. Martin SS, Qasim AN, Mehta NN, Wolfe M, Terembula K, Schwartz S, Iqbal N, Schutta M, Bagheri R, Reilly MP. Apolipoprotein B but not LDL cholesterol is associated with coronary artery calcification in type 2 diabetic whites. Diabetes 2009, 58:1887-1892. 10.2337/db08-1794, 2712798, 19491209.
39. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2008, 51:1512-1524. 10.1016/j.jacc.2008.02.034, 18402913.
40. Ouguerram K, Magot T, Zair Y, Marchini JS, Charbonnel B, Laouenan H, Krempf M. Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes. J Pharmacol Exp Ther 2003, 306:332-337. 10.1124/jpet.103.048991, 12684543.
41. Duvillard L, Pont F, Florentin E, Gambert P, Verges B. Significant improvement of apolipoprotein B-containing lipoprotein metabolism by insulin treatment in patients with non-insulin-dependent diabetes mellitus. Diabetologia 2000, 43:27-35. 10.1007/s001250050004, 10990093.